1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: BGSM-74484, NCI-V85-0227
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: EST-1586
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: NYH-068004-087, NCI-V86-0129
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: YALE-HIC-3709, NCI-V86-0094
|
|
5.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 1 to 21
Sponsor: NCI
Protocol IDs: POG-8741/42, POG-8741, POG-8742
|
|
6.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 85 and under
Sponsor:
Protocol IDs: EORTC-30869
|
|
7.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor:
Protocol IDs: EORTC-62901
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: pre-/perimenopausal
Sponsor:
Protocol IDs: CAN-NCIC-MA12, NCI-V93-0323, NCT00002542, MA12
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: any age
Sponsor:
Protocol IDs: EORTC-10920
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: MRC-BS07, EU-94028
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Other
Protocol IDs: MRC-ST02, EU-94035, NCT00002615
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENENTECH-HO648G, NCI-V95-0714
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor:
Protocol IDs: DAN-DBCG-94-03, EU-95008
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: under 15 at initial diagnosis
Sponsor:
Protocol IDs: MRC-LEUK-UKALL-R2, EU-95039
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 16 to 65
Sponsor:
Protocol IDs: IBCSG-15-95, EU-96021, NCT00002784
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 74
Sponsor:
Protocol IDs: DAN-DBCG-9505, SBG-94-1, EU-95010
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: under 60
Sponsor:
Protocol IDs: FRE-FNCLCC-PEGASE03, EU-96032, NCT00002870
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: under 65
Sponsor:
Protocol IDs: FRE-FNCLCC-GFEA-09, EU-96015, FRE-GFEA-09
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 18
Sponsor: Other
Protocol IDs: SIOP-MMT-95, EU-96035, NCT00002898
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 70 and under
Sponsor:
Protocol IDs: CNR-012307, EU-95017
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor:
Protocol IDs: MRC-UKCCCR-AB01, EU-97002, NCT00002953
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor:
Protocol IDs: SCTN-BR9601, EU-97013, NCT00003012
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 60
Sponsor:
Protocol IDs: FRE-FNCLCC-PEGASE01, EU-96030
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: Other
Protocol IDs: CRC-TU-NEAT, EU-98041, NCT00003577
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor:
Protocol IDs: FRE-FNCLCC-95012, EU-98021, NCT00003606
|
